Navigation Links
Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society

afety. HUMIRA is a registered trademark of Abbott Laboratories.

The data from this clinical trial support the study hypothesis that rHuPH20 increases the relative bioavailability of the SC injected HUMIRA:

    -- For the primary endpoint of area under the curve (AUC) for adalimumab

       plasma concentration, the AUC over the 14 days following administration

       was higher when the HUMIRA was co-injected with rHuPH20 compared to the

       HUMIRA injection without rHuPH20 for 100% (15/15) of the patients in

       the study.


    -- The modeled population PK analysis estimated a 59% maximal increase in

       the relative SC bioavailability of adalimumab at steady state if

       co-injected with rHuPH20; thus, the reported reference 64% SC absolute

       bioavailability HUMIRA injected alone was estimated to increase to 100%

       when co-injected with rHuPH20, achieving essentially complete

       absorption.


    -- The modeled PK analysis estimated that a high dose of rHuPH20 (at least

       6,400 U) was required to assure the maximal rHuPH20 effect.


    -- Injection of rHuPH20 with HUMIRA was well tolerated at all rHuPH20 dose

       levels, without dose-limiting toxicity, premature withdrawals, or

       serious adverse events.  Of the total of five adverse events reported

       in this study, two were assessed as having no association with either

       study drug (basal cell carcinoma and urinary tract infection).  The

       remaining three events consisted of mild injection site erythema

       (redness) that occurred on the day of the co-injection and resolved

       within one or two days.

As a spreading agent, hyaluronidase has traditionally been used to accelerate the delivery of drugs and fluids, including local anesthetics, other co-injected drugs, and contrast agents, and for subcutaneous fluid replacement. Although a large body of clinical experience supports the benefits and safety of using
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
7. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
10. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
11. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
Post Your Comments:
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
(Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Pharmaceuticals, a,private biotechnology company discovering and developing ... a proof-of-concept clinical trial of,SLC022 in patients ... of shingles, affects approximately 200,000 people a ... is an international, multi-center,placebo-controlled study that will ...
... InterMune, Inc.,(Nasdaq: ITMN ) today announced that ... January 12 at 8:30 a.m. EST to discuss results ... (HCV) protease inhibitor ITMN-191,(R7227) in combination with Pegasys(R) (interferon ... genotype 1. ITMN-191 is,being developed in collaboration with Roche. ...
Cached Medicine Technology:Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia 2InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191 2
(Date:4/18/2014)... made a discovery that turns 160 years of neuroanatomy ... long known to be essential for the fast transmission ... not as ubiquitous as thought, according to a new ... Stem Cell Institute (HSCI) and the University,s Department of ... Jeff Lichtman, of Harvard,s Department of Molecular and Cellular ...
(Date:4/18/2014)... memories? How did it make you feel? According to ... experience, such as how sad you were or how ... when you can,t stop thinking about it. , ... context of the memories, rather than how you felt, ... the negative effects of these memories, a new study ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... The presence of chronic inflammation in benign prostate ... cancer, and this association was found even in ... to a study published in Cancer Epidemiology, ... American Association for Cancer Research. , An analysis ... of the placebo arm of the Prostate Cancer ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... WEIFANG, Shandong, China, May 15 /PRNewswire-Asia-FirstCall/ -- Shengtai,Pharmaceutical, ... Company"),a leading manufacturer and distributor of high-quality, pharmaceutical ... results for the,third quarter of fiscal 2009 ended ... "The global economic environment has impacted our operations ...
... ENDO ), an innovative medical device company ... by urologists and interventional radiologists for tissue and tumor ... March 31, 2009. Highlights of the quarter include ... revenues for the first quarter of 2009 were $8.2 ...
... international thought leaders featured -SAN FRANCISCO, May 15 ... clinical trial management systems, this week hosted a constellation ... partners at its annual meeting in San Francisco. Velos ... variety of initiatives and to hear speakers from ...
... Makes Scholarship Awards Available for Top Talent in Non-Profit Sector ... ... 15, 2009 -- In recognition of the talented businesswomen in ... awards to the prestigious Menttium 100® leadership development program. , ...
... Manitoba , ... Steinbach, Manitoba, Canada (Vocus) May 15, 2009 -- Each ... Even pop singer, famed choreographer, and American Idol judge, Paula Abdul recently ... issue of Ladies Home Journal. While Abdul admits to being addicted to ...
... of a new research grant program, open to researchers from academic ... ... May 15, 2009 -- Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today ... researchers from academic and non-profit institutions across North America. , ...
Cached Medicine News:Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 2Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 3Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 4Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 5Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 6Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 7Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 8Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 9Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 10Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 11Health News:Shengtai Pharmaceutical, Inc. Reports Unaudited Third Quarter Fiscal 2009 Financial Results 12Health News:Endocare Reports 2009 First Quarter Financial Results 2Health News:Endocare Reports 2009 First Quarter Financial Results 3Health News:Endocare Reports 2009 First Quarter Financial Results 4Health News:Endocare Reports 2009 First Quarter Financial Results 5Health News:Endocare Reports 2009 First Quarter Financial Results 6Health News:Endocare Reports 2009 First Quarter Financial Results 7Health News:Endocare Reports 2009 First Quarter Financial Results 8Health News:Endocare Reports 2009 First Quarter Financial Results 9Health News:Endocare Reports 2009 First Quarter Financial Results 10Health News:Endocare Reports 2009 First Quarter Financial Results 11Health News:Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting 2Health News:Top Academic Medical Centers, Research Institutions, Partners Gather, Share Experiences, Success Stories at Velos Annual Meeting 3Health News:Menttium Offers Scholarship Award to Businesswomen Leaders 2Health News:Chronic Pain Sufferers Find Hope in the Darkness 2Health News:Exiqon Announces New Grant Program for MicroRNA Research 2
... opening to block tear drainage through the ... dry eye symptoms, and enable the eye ... tears:, Low-profile cap design virtually eliminates ... facilitates easy removal with jewelers forceps, if ...
Extended Duration absorbable plugs are designed to provide patient comfort for up to 3 months. This long lasting plug is effective and economical for transient dry eye symptoms following surgery. Ext...
Attain Left-heart Lead Delivery Systems. Medtronic offers left-heart lead delivery systems to assist with accessing the coronary sinus (cs)....
Attain™ Left-heart Lead Options to Fit Your Patient's Anatomy. Navigate moderately to greatly angled veins with high tortuosity....
Medicine Products: